Ask AI
AJX 101
AJX-101: Phase I Study of AJ1-11095, a Type II JAK2 Inhibitor, in Patients With Myelofibrosis After Prior Type I JAK2 Inhibitor Treatment

Released: June 26, 2026

Activity

Progress
1
Course Completed
Activity Information

Released: June 26, 2026